Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer

Related Experiment Video

Updated: Feb 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K

Namita Sharma1, Stephen Graziano2

  • 1Hematology/Medical Oncology, GCMC Cancer Center, 1800 Mulberry Street, Scranton, PA 18510, United States.

Cancer Treatment Reviews
|July 18, 2018
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) are effective for EGFR-mutated non-small cell lung cancer (NSCLC). Afatinib, an irreversible ErbB blocker, was evaluated in the LUX-Lung trials for advanced NSCLC management.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Tyrosine kinase inhibitors (TKIs) are standard first-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC).
  • Erlotinib and gefitinib, initial TKIs, demonstrated superior response rates over chemotherapy.
  • Afatinib, an irreversible ErbB family blocker, exhibits activity in EGFR-mutated NSCLC.

Purpose of the Study:

  • To review data from the LUX-Lung trial program evaluating afatinib in advanced NSCLC.
  • To assess the efficacy of afatinib in first-, second-, and third-line settings for NSCLC.

Main Methods:

  • Review of data from 8 reported LUX-Lung trials.
  • Analysis of clinical trial outcomes for afatinib in advanced NSCLC patients with EGFR mutations.

Main Results:

  • Erlotinib and gefitinib showed improved response rates compared to chemotherapy.
  • Afatinib demonstrated activity in EGFR-mutated NSCLC across different treatment lines.

Conclusions:

  • TKIs, including afatinib, represent a significant advancement in treating EGFR-mutated advanced NSCLC.
  • The LUX-Lung trials provide comprehensive data on afatinib's role in NSCLC management.
Keywords:
AfatinibEpidermal growth factor receptorErbB receptorsNon-small cell lung cancerTyrosine kinase inhibitor

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

419
Method of Isolated Ex Vivo Lung Perfusion in a Rat Model: Lessons Learned from Developing a Rat EVLP Program08:59

Method of Isolated Ex Vivo Lung Perfusion in a Rat Model: Lessons Learned from Developing a Rat EVLP Program

Published on: February 25, 2015

28.6K

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Pleura of the Lungs01:13

Pleura of the Lungs

The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
7.4K
Gross Anatomy of the Lungs01:17

Gross Anatomy of the Lungs

The lungs are a pair of vital organs connected to the trachea via the left and right bronchi. The base of these organs meets the dome-shaped muscle known as the diaphragm. Encased by the pleurae, the lungs contact the mediastinum. The right lung is shorter yet wider, and has a larger volume than the left lung. The left lung has an indentation known as the cardiac notch. The superior region of the lungs is referred to as the apex, whereas the base is the lower region near the diaphragm. The...
4.8K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K